D-Wave Quantum's Mixed Signals: Record Bookings, a Revenue Gap, and a Scientific Storm

D-Wave Quantum's bookings surge 2,000% but revenue misses estimates; a new study threatens quantum advantage claim, and CFO sells $9.1M in stock.

D-Wave Quantum has become a case study in contradiction. The quantum computing company posted a staggering 2,000% surge in bookings for its fiscal first quarter, landed tens of millions in federal backing, and saw its chief financial officer cash out nearly $9.1 million in stock — all while a new academic study threatens to undermine its most prized technical claim.

The result is a stock that swings violently, with annualized volatility of 133%, and a valuation of roughly $10.2 billion hinging almost entirely on promises rather than realized revenue.

A Scientific Salvo at the Core Value Proposition

The Flatiron Institute published research arguing that classical algorithms running on off-the-shelf hardware can replicate calculations that D-Wave had long presented as proof of "quantum advantage." The institute used ITensor software to simulate the very benchmarks D-Wave used as its flagship evidence.

CEO Alan Baratz pushed back hard, saying the study failed to capture the full scope and complexity of the company's internal benchmarks. The defense did little to calm investors. Shares fell around 5.4% on Wednesday to $27.82, halting a 50% rally from earlier in the week. The stock has since drifted to around $23.75 in euro-denominated trading — up roughly 54% over the past 30 days but still 38% below its 52-week high of $38.48.

Some analysts remain sanguine, setting an average price target of $35.17. But if other independent labs confirm the Flatiron findings, the entire edifice of D-Wave's valuation could come under renewed pressure. The quantum advantage claim is, after all, the company's central sales argument.

CFO's $9.1 Million Exit

On May 22, Chief Financial Officer John Markovich sold 328,752 shares at a weighted average price of $27.70 each, netting approximately $9.1 million. The sale followed the exercise of options with strike prices between $0.85 and $0.92. After the transaction, Markovich still holds 1.44 million shares directly, including nearly 448,000 unvested restricted stock units.

The timing — coinciding with the scientific controversy and the stock's pullback — drew attention, though insider sales are common after option exercises.

Bookings Explode, but Revenue Dives

The Q1 2026 earnings report presented a split picture that puzzled many on Wall Street. Bookings hit a record $33.4 million, a nearly 2,000% leap from the same period last year. Yet realized revenue came in at just $2.86 million, missing the consensus estimate of roughly $4.14 million and tumbling 81% year-over-year.

The collapse was largely due to a one-off system sale in the prior-year period that distorted the comparison. On the bottom line, the company surprised positively: the net loss of $0.05 per share beat the expected $0.08 loss. D-Wave's cash position stood at $588 million at the end of March.

The disconnect between bookings and revenue explains the elevated market capitalization: investors are betting the backlog will convert into cash flow over time. The key question is when — and how reliably.

Federal Support Provides a Backstop

While the scientific debate and quarterly results generate headlines, D-Wave continues to deepen its relationship with Washington. The company signed a non-binding letter of intent for approximately $100 million from the CHIPS and Science Act, earmarked for developing a 100,000-qubit annealing system. In return, the U.S. government would receive an equity stake.

Separately, its subsidiary Quantum Circuits LLC entered the second phase of the SQFab project, a $25 million program run through the NORDTECH consortium and the U.S. Department of Defense, focused on advancing superconducting qubit manufacturing.

The Next Litmus Test: London in June

On June 18, D-Wave will take the stage at Qubits Europe 2026 in London, where it plans to demonstrate real-world use cases for its dual-platform architecture in logistics, artificial intelligence, and materials science. For a stock that trades almost entirely on expectation, concrete proof points could do more for the share price than any earnings beat. The London event will test whether the company can turn abstract roadmap promises into tangible demonstrations — and whether the scientific shadow cast by the Flatiron study can be dispelled.